A Study of Disease Progression and Anti-HIV Treatments
Status:
Completed
Trial end date:
1998-10-01
Target enrollment:
Participant gender:
Summary
To determine the influence of virus load, CD4 count, biologic phenotype, and presence of
symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen.
PER AMENDMENT 8/27/96: To extend the availability of currently assigned ACTG 303 treatment
for 6 months.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)